



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

GEALL *et al.*

Appl. No.: 10/725,015

Filed: December 2, 2003

For: **Method for Producing Sterile
Polynucleotide Based
Medicaments**

Confirmation No.: 3181

Art Unit: 1635

Examiner: SCHNIZER, Richard A.

Atty. Docket: 1530.0610001/EJH/UWJ

**Third Supplemental Information Disclosure Statement
Under 37 C.F.R. § 1.97(b)**

Mail Stop RCE

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms, PTO/SB/08A and PTO/SB/08B, are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Third Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Second Supplemental Information Disclosure Statement filed on January 13, 2006 in connection with the above-captioned application.

Copies of documents **FP1** and **NPL1** to **NPL38** are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and patent application publications, documents **US1** to **US16**, cited on the attached IDS Form PTO/SB/08A are not submitted.

The Examiner's attention is directed to the following co-pending U.S. Patent Applications, which are directed to related technical subject matter:

U.S. Application No. 10/658,688, inventor Hermanson, G.G., filed September 10, 2003, now published as U.S. Publication No. 2007/0105799 A1 and listed as document **US16**;

U.S. Application No. 10/843,656, inventors Vilalta *et al.*, filed May 12, 2004, now published as U.S. Publication No. 2007/0105193 A1 and listed as document **US15**;

U.S. Application No. 10/965,238, inventors Hobart *et al.*, filed October 15, 2004, now published as U.S. Publication No. 2005/0065107 A1 and listed as document **US12**;

U.S. Application No. 11/131,479, inventors Luke *et al.*, filed May 18, 2005, now published as U.S. Publication No. 2006/0024670 A1 and listed as document **US13**;

U.S. Application No. 11/292,280, inventor Geall, A., filed December 2, 2005, now published as U.S. Publication No. 2006/0134221 A1 and listed as document **US14**;

The identification of these U.S. Patent Applications is not to be construed as a waiver of secrecy as to those applications now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited applications and the art cited therein during examination.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is

not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.


This Information Disclosure Statement is being filed before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. § 1.114. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Ulrike Winkler Jenks
Attorney for Applicants
Registration No. 59,044

Date: October 31, 2007

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600
742062v1